Do you have any worries that the low dosages in the first 3 cohorts will cause very little positive data and the good news as to data won't occur til further down the line?

On one hand due to the low starting doses I feel the first 3 cohorts may show little effect, but on the other hand if they didn't have positive findings I doubt DF would be presenting at ASCO and sending their top man to do the presentation.

Will wait with confidence.

Nice to know only about 6 months tops before we have a pretty good handle on Kevetrin with always the possibility something even better as to timing pops up earlier.